Nexalin Technology Awarded U.S. Patent #12011591: Transcranial alternating current dynamic frequency stimulation (TACS) method for Alzheimers and Dementia
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology has been awarded U.S. Patent #12011591 for its transcranial alternating current dynamic frequency stimulation (TACS) method, aimed at treating Alzheimer's and Dementia.
June 18, 2024 | 7:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nexalin Technology has received a U.S. patent for its TACS method, which is designed to treat Alzheimer's and Dementia. This patent could enhance the company's market position and attract investor interest.
The award of a U.S. patent for a novel treatment method can significantly boost Nexalin Technology's market position and investor confidence. This development is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100